西亚试剂:A banner year for Berkeley, CA-based Aduro just got better

发布时间：2025-09-27

A banner year for Berkeley, CA-based Aduro just got better. The biotech has inked its second licensing pact of the year with Johnson & Johnson ($JNJ), which kicked in a $30 million upfront and boosted its total milestone package to the $1 billion-plus category.

With the J&J Innovation Center in the Bay Area leading the way, the pharma giant grabbed rights to new product candidates for lung and other types of cancer, convinced that Aduro's platform tech holds great promise for beefing up its oncology pipeline. J&J's $817 million deal includes potential milestones for successful development efforts as it hitched a ride on a tech platform focused on the ability of engineered Listeria monocytogenes strains to kick up an immune response against cancer.

Immunotherapies have emerged as the single hottest R&D strategy of the year. And Aduro, a 2014 Fierce 15 company, has attracted close attention for its use of a failed cancer vaccine--GVAX--as part of a combo approach to direct an attack on cancer. J&J is known for making ambitious plays in this field when it finds a new technology that it likes. And the pharma giant appears to be all in on Aduro.

Back in May J&J signed a $365 million deal covering prostate cancer, a major focus for J&J. The pharma giant also kicked in for a recent $55 million venture round to fund an expanded Phase IIb trial of its cancer combo, which is enrolling about 240 patients into three treatment arms: one receiving the combination treatment, one taking CRS-207 alone and another on standard chemotherapy. The study's primary endpoint is overall survival, and Aduro hopes it'll back up the safety, immune response and efficacy CRS-207 and GVAX have demonstrated thus far.

Aduro is one of the few small biotechs in the cancer field to win a breakthrough drug designation from the FDA. The BTD is designed to grease the regulatory skids for promising new therapies.

"We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer," said Stephen Isaacs, chairman, president and chief executive officer of Aduro. "Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."

• 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   
• 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购

上一篇：航锦科技拟控制权变更
下一篇：辽宁省发布辽宁省污染防治与生态建设和保护攻坚行动计划